Literature DB >> 35846416

Pretreatment 18F-FDG PET/CT-Derived Parameters in Predicting Clinical Outcomes of Locally Advanced Upper Third Esophageal Squamous Cell Carcinoma After Definitive Chemoradiation Therapy.

Le Ngoc Ha1, Nguyen Dinh Chau2, Bui Quang Bieu2, Mai Hong Son1.   

Abstract

Purpose: The aim of this study was to investigate whether standard uptake values (SUVs) of pretreatment 18F-FDG PET/CT were the surrogate parameters for predicting the outcomes in locally advanced esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Materials and
Methods: Sixty patients with esophageal squamous cell carcinoma underwent pretreatment 18F-FDG PET/CT and received definitive chemoradiotherapy. 18F-FDG metabolic parameters including SUVmax, SUVmean, SULpeak, total lesion glycolysis (TLG), and metabolic tumor volume (MTV) of primary tumor were calculated. The receiver-operating characteristic (ROC) curve was used to determine the optimal cutoff value of FDG PET/CT-derived parameters that associated with treatment response. Estimating progression-free survival (PFS) and overall survival (OS) was analyzed by using Kaplan-Meier methods. Univariate and multivariate analysis for PFS and OS was performed using Cox regression.
Results: Complete response was achieved in 38.3%. The 4-year OS and PFS rates were 48.6% and 44.4%, respectively. SUVmean with a cutoff value of 6.1 could predict complete response with sensitivity of 69.6%, specificity of 78.4%, and accuracy of 75%. Cox multi-factor regression analyses revealed SUVmean > 6.1 as an independent prognostic factor for OS (HR = 6.74, p = 0.02) and PFS (HR = 6.53, p < 0.001). Conclusions: Our study suggests that SUVmean of the primary tumor in pretreatment 18F-FDG PET/CT may be used as an independent predictor in esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
© The Author(s), under exclusive licence to Korean Society of Nuclear Medicine 2022.

Entities:  

Keywords:  18F-FDG PET/CT; Definitive chemoradiotherapy; Esophageal squamous cell carcinoma; Prognosis; SUVmean; Standard uptake value

Year:  2022        PMID: 35846416      PMCID: PMC9276877          DOI: 10.1007/s13139-022-00751-9

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  38 in total

Review 1.  A systematic review of the factors affecting accuracy of SUV measurements.

Authors:  Michael C Adams; Timothy G Turkington; Joshua M Wilson; Terence Z Wong
Journal:  AJR Am J Roentgenol       Date:  2010-08       Impact factor: 3.959

2.  Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?

Authors:  Anna R Cervino; Laura Evangelista; Rita Alfieri; Carlo Castoro; Vanna Chiarion Sileni; Fabio Pomerri; Luigi Corti; Pier C Muzzio
Journal:  J Cancer Res Ther       Date:  2012 Oct-Dec       Impact factor: 1.805

3.  Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern.

Authors:  E Versteijne; H W M van Laarhoven; J E van Hooft; R M van Os; E D Geijsen; M I van Berge Henegouwen; M C C M Hulshof
Journal:  Dis Esophagus       Date:  2014-04-11       Impact factor: 3.429

4.  Impact of PET/CT on radiation treatment in patients with esophageal cancer: A systematic review.

Authors:  Jing Lu; Xiang-Dong Sun; Xi Yang; Xin-Yu Tang; Qin Qin; Hong-Cheng Zhu; Hong-Yan Cheng; Xin-Chen Sun
Journal:  Crit Rev Oncol Hematol       Date:  2016-09-13       Impact factor: 6.312

Review 5.  Oesophageal cancer.

Authors:  Jesper Lagergren; Elizabeth Smyth; David Cunningham; Pernilla Lagergren
Journal:  Lancet       Date:  2017-06-22       Impact factor: 79.321

6.  Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.

Authors:  Nabil P Rizk; Laura Tang; Prasad S Adusumilli; Manjit S Bains; Timothy J Akhurst; David Ilson; Karyn Goodman; Valerie W Rusch
Journal:  J Thorac Oncol       Date:  2009-07       Impact factor: 15.609

7.  PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma.

Authors:  Rachel L G M Blom; Inge R Steenbakkers; Guido Lammering; Roy F A Vliegen; Eric J Belgers; Charlotte de Jonge; Wendy M J Schreurs; Marius Nap; Meindert N Sosef
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-06-14       Impact factor: 9.236

8.  Good prediction of treatment responses to neoadjuvant chemoradiotherapy for esophageal cancer based on preoperative inflammatory status and tumor glucose metabolism.

Authors:  Chuan Li; Jing-Wei Lin; Hui-Ling Yeh; Cheng-Yen Chuang; Chien-Chih Chen
Journal:  Sci Rep       Date:  2021-06-02       Impact factor: 4.379

9.  Does Metastatic Lymph Node SUVmax Predict Survival in Patients with Esophageal Cancer?

Authors:  Betül Vatankulu; Yasemin Şanlı; Esra Kaytan Sağlam; Serkan Kuyumcu; Zeynep Gözde Özkan; Ebru Yılmaz; Sevim Purisa; Işık Adalet
Journal:  Mol Imaging Radionucl Ther       Date:  2015-10-05

10.  18F- FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer.

Authors:  Styliani Mantziari; Anastasia Pomoni; John O Prior; Michael Winiker; Pierre Allemann; Nicolas Demartines; Markus Schäfer
Journal:  BMC Med Imaging       Date:  2020-01-22       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.